BLADDER CANCER
 
Bladder Ca: Genetic testing, targeted therapies signal new era
Arlene Siefker-Radtke, MD, Yair Lotan, MD, Elizabeth Plimack, MD, MS, and Badrinath Konety, MD, MBA, share their perspectives on current and future developments in bladder cancer.
Learn more
ADVERTISEMENT
 
Study examines financial toxicity in bladder cancer patients
Financial toxicity is prevalent among patients with bladder cancer, according to findings from a cross-sectional study.
Get the data
ADVERTISEMENT
Visit a Cysview® Reference Center in TX, OH, or CA
See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations.
 
 
MORE FROM UROLOGY TIMES
 
Worse perioperative outcomes seen in bladder Ca patients ≥80 years
FDA approves enfortumab for locally advanced or metastatic urothelial Ca
ADVERTISEMENT
AR-targeted therapies: progress for mCRPC
In this Urology Times® supplement, a roundtable of expert urologists and oncologists addresses common questions about patient evaluation and management of castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC Read it now.
 
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont